Literature DB >> 8912566

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.

N J Lowe1, J M Wieder, A Rosenbach, K Johnson, R Kunkel, C Bainbridge, T Bourget, I Dimov, K Simpson, E Glass, M T Grabie.   

Abstract

BACKGROUND: The effectiveness of cyclosporine in the treatment of severe psoriasis is well known.
OBJECTIVE: We evaluated the efficacy and toxicity of systemic cyclosporine in patients with severe psoriasis, observing short-term (12 weeks) and long-term (3 to 5 years) effects.
METHODS: To further elucidate efficacy and safety, 42 patients with severe psoriasis were treated initially with cyclosporine 5 to 6 mg/kg per day for 12 weeks. A subset of 14 patients continued maintenance treatment for 3.5 years to study the long-term effects of cyclosporine on renal function and structure. Renal biopsies were performed after 2.5 years and 3.5 years of treatment. Renal histologic findings were correlated with renal function.
RESULTS: By weeks 8 and 12, 64% (n = 27) and 86% (n = 36) of patients, respectively, were rated clear or almost clear of the psoriasis. However, a subpopulation of 15 patients did not respond to 5 mg/kg daily but improved when the dose was increased to 6 mg/kg daily. Clearance or near clearance was achieved in 67% of this subpopulation after 4 weeks. For the 29 patients whose glomerular filtration rate (GFR) was measured, mean GFR fell by 7% from baseline to week 4 (p < 0.05). This change was reversible when dosage was reduced by 1 mg/kg per day in each of these patients. Patients older than 45 years of age experienced significant elevation of mean diastolic blood pressure and had reduced GFR and increased serum creatinine. After 2.5 years, of the 14 patients who continued maintenance treatment, two had biopsy specimens that showed moderate interstitial fibrosis and tubular atrophy. The remainder showed only minimal to mild structural damage. After 3.5 years of cyclosporine treatment, repeat renal biopsy specimens revealed slight increases in structural changes in nine subjects. These changes correlated with increasing age and drug-induced hypertension.
CONCLUSION: We conclude that 5 mg/kg of cyclosporine daily is usually an effective initial dose for psoriasis. Patients who do not respond will often benefit from elevation of the dose to 6 mg/kg daily. Older patients experience cyclosporine-induced hypertension and changes in renal function and structure more frequently than do younger patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912566     DOI: 10.1016/s0190-9622(96)90726-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis.

Authors:  Eun Ju Lee; Min Kyung Shin; Nack In Kim
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

Review 2.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.

Authors:  Xiaofei He; Aixia Dou; Saran Feng; Ashley Roman-Rivera; Caleb Hawkins; Lauren Lawley; Jiajia Zhang; Mark Wunderlich; Benjamin Mizukawa; Stephanie Halene; Amisha Patel; Jing Fang
Journal:  Exp Hematol       Date:  2020-05-08       Impact factor: 3.084

5.  Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).

Authors:  M S Salek; A Y Finlay; J J C Lewis; M I Sumner
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

6.  Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

Authors:  Tiffani Hamilton; Alan Menter; Ivor Caro; Peter Compton; Jeffrey Sobell; Kim A Papp
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature.

Authors:  Deepak M W Balak; Sascha Gerdes; Aurora Parodi; Laura Salgado-Boquete
Journal:  Dermatol Ther (Heidelb)       Date:  2020-06-11

8.  Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles.

Authors:  Abderrazzaq Essaghraoui; Ahmed Belfkira; Bassou Hamdaoui; Cláudia Nunes; Sofia A Costa Lima; Salette Reis
Journal:  Nanomaterials (Basel)       Date:  2019-08-27       Impact factor: 5.076

9.  Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.

Authors:  C Leonardi; A Menter; T Hamilton; I Caro; B Xing; A B Gottlieb
Journal:  Br J Dermatol       Date:  2008-03-27       Impact factor: 9.302

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.